Lokesh Bontha Venkata Subrahmanya, Prasad Y Rajendra, Shaik Afzal Basha
Faculty of Pharmaceutical Sciences, UCSI University, Kuala Lumpur, Malaysia.
AU College of Pharmaceutical Sciences, Andhra University, Visakhapatnam, India.
Infect Disord Drug Targets. 2019;19(3):310-321. doi: 10.2174/1871526519666181217120626.
Many synthetic procedures were reported till date to prepare pyrazoline derivatives. Some have published pyrazolines from different chalcone derivatives in the literature.
A series of new pyrazolines containing novel 2,5-dichloro-3-acetylthiophene chalcone moiety (PZT1-PZT20) have been synthesized, characterized by 1HNMR and 13CNMR and evaluated for them in vitro antitubercular activity against M. tuberculosis H37Rv strain and in vitro anticancer activity against DU-145 prostate cancer cell lines and all compounds were also screened for molecular docking studies against specific targeted protein domains.
All compounds were screened for potential activity against Mycobacterium tuberculosis H37Rv (MTB) strain and anticancer activity against DU-149 prostate cancer cell lines using MTT cytotoxicity assay.
Among the series, compound PZT5 with 2", 4"-dichlorophenyl group at 5-position on the pyrazoline ring exhibited the most potent antitubercular activity (MIC=1.60 µg/mL) and compounds PZT2, PZT9, PZT11, PZT15, and PZT20 showed similar antitubercular activity against standard pyrazinamide (MIC=3.12 µg/mL) by broth dilution assay. PZT15 and PZT17 with 4"- pyridinyl and 2"-pyrrolyl groups on pyrazoline ring were found to exhibit better anticancer activity against DU-149 prostate cancer cell lines with IC50 values of 2.0±0.2 µg/mL and 6.0±0.3 µg/mL respectively by MTT assay. The preliminary structure-activity relationship has been summarized. The molecular docking studies with crystalline structures of enoyl acyl carrier protein reductase InhA interaction with target protein (2NSD; PDB and 3FNG; PDB) of Mycobacterium tuberculosis H37Rv (MTB) strain have also exhibited good ligand interaction and binding affinity. Ligand interaction and binding affinity were estimated using crystal structures of both types of enoyl acyl carrier protein reductase InhA (3FNG.pdb) and found to be much higher (-16.70 to - 19.20 kcal/mol) compared with pyrazinamide (-10.70 kcal/mol) as a standard target molecule. Whereas the binding affinities of six active compounds with crystal structure of other type of enoyl acyl carrier protein reductase InhA (2NSD.pdb) were much similar and higher (-9.30 to - 11.20 kcal/mole) than pyrazinamide (-11.10 kcal/mole).
These new pyrazolines would be promising potent inhibitors of drug sensitive and drug resistant Mycobacterium tuberculosis strain and potential anticancer agents against prostate cancer and other prototypes of cancers.
迄今为止,已报道了许多合成吡唑啉衍生物的方法。文献中已有一些从不同查尔酮衍生物制备吡唑啉的报道。
合成了一系列含有新型2,5 - 二氯 - 3 - 乙酰基噻吩查尔酮部分的新型吡唑啉(PZT1 - PZT20),通过1HNMR和13CNMR对其进行表征,并评估它们对结核分枝杆菌H37Rv菌株的体外抗结核活性以及对DU - 145前列腺癌细胞系的体外抗癌活性,还对所有化合物针对特定靶向蛋白结构域进行了分子对接研究。
使用MTT细胞毒性试验筛选所有化合物对结核分枝杆菌H37Rv(MTB)菌株的潜在活性以及对DU - 149前列腺癌细胞系的抗癌活性。
在该系列中,吡唑啉环5位带有2", 4"-二氯苯基的化合物PZT5表现出最强的抗结核活性(MIC = 1.60 µg/mL),通过肉汤稀释法,化合物PZT2、PZT9、PZT11、PZT15和PZT20对标准吡嗪酰胺(MIC = 3.12 µg/mL)表现出相似的抗结核活性。通过MTT试验发现,吡唑啉环上带有4"-吡啶基和2"-吡咯基的PZT15和PZT17对DU - 149前列腺癌细胞系表现出较好的抗癌活性,IC50值分别为2.0±0.2 µg/mL和6.0±0.3 µg/mL。总结了初步的构效关系。对结核分枝杆菌H37Rv(MTB)菌株的烯酰基酰基载体蛋白还原酶InhA与靶蛋白(2NSD;PDB和3FNG;PDB)的晶体结构进行的分子对接研究也显示出良好的配体相互作用和结合亲和力。使用两种类型的烯酰基酰基载体蛋白还原酶InhA(3FNG.pdb)的晶体结构估计配体相互作用和结合亲和力,发现与作为标准靶分子的吡嗪酰胺(-10.70 kcal/mol)相比要高得多(-16.70至-19.20 kcal/mol)。而六种活性化合物与另一种类型的烯酰基酰基载体蛋白还原酶InhA(2NSD.pdb)晶体结构的结合亲和力与吡嗪酰胺(-11.10 kcal/mol)相比非常相似且更高(-9.30至-11.20 kcal/mol)。
这些新型吡唑啉有望成为对药物敏感和耐药结核分枝杆菌菌株的有效抑制剂,以及针对前列腺癌和其他癌症原型的潜在抗癌药物。